Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

37 results about "Tumor-Related Protein" patented technology

Normal proteins that, when altered or inappropriately expressed, contribute to tumor cell growth, proliferation, progression or metastasis.

Methods and materials for detecting colorectal neoplasm

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor associated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES

Antigen covalently bound chitosan nanoparticle-based nasal immune carrier

The invention belongs to the technical field of medicines, and relates to an antigen covalently bound chitosan nanoparticle-based nasal immune carrier and a preparation method thereof. The carrier is composed of a nanoparticle and an antigen, the antigen is covalently bound to the surface of the nanoparticle, and the nanoparticle is prepared by adopting a raw material chitosan and its derivatives; and the antigen is selected from from infectious diseases or tumors related proteins or polypeptides. The carrier can significantly improve the neck lymph node targeting of people nasally dosed with the antigen proteins or polypeptides, enhances the mucosal and systemic immune response, has the advantages of simple preparation, stable process, high antigen utilization rate, difficult antigen shedding, benefiting of the improvement of the cervical lymph node transportation of the antigens, good nasal immune effect and no nasal mucosa toxicity, and is suitable for preventing respiratory infectious diseases.
Owner:FUDAN UNIV

Vector for anti-hpv vaccine and transformed microorganism by the vector

Expression vectors are described that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one or more than two genes selected from among pgsB, pgsC and pgsA, encoding a poly-χ-glutamic acid synthetase complex (pgsBCA) of a Bacillus sp. strain, and genes that encode virion capsid proteins, tumor-associated proteins of human papillomavirus. Methodology for preparing the foregoing vectors, vaccines and transformed microorganisms are also described.
Owner:BIOLEADERS CORP

Targeted identification of immunogenic peptides

This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and / or foreign proteins from infectious organisms for specific and / or enhanced expression only in the presence of the antibody.
Owner:THE HENRY M JACKSON FOUND FOR THE ADVANCEMENT OF MILITARY MEDICINE INC

Prodrugs of cytotoxic active agents having enzymatically cleavable groups

The invention relates to novel prodrugs or conjugates of the general formula (Ia)in which La, n, R and D have the definitions given in the description and which have a structural motif reduced to an asparagine derivative as cleavage site for tumour-associated proteases such as legumain, in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are released by legumain cleavage, and to the use of these prodrugs or conjugates for treatment and / or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and / or prevention of diseases, especially of hyperproliferative and / or angiogenic disorders, for example cancers. Reduction of the legumain-cleavable substrate peptide sequence to an asparagine derivative as structural motif, as a result of slowed legumain cleavage, achieves an increase in stability in the lysosomes of healthy organs while simultaneously maintaining the high anti-tumour effect.
Owner:BAYER AG +1

Vector for anti-HPV vaccine and transformed microorganism by the vector

Expression vectors are described that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one or more than two genes selected from among pgsB, pgsC and pgsA, encoding a poly-χ-glutamic acid synthetase complex (pgsBCA) of a Bacillus sp. strain, and genes that encode virion capsid proteins, tumor-associated proteins of human papillomavirus, Methodology for preparing the foregoing vectors, vaccines and transformed microorganisms are also described.
Owner:BIOLEADERS CORP

Preparation method of trichina and tumor related protein gene and medical application

The invention provides a trichina and tumor cell related protein gene. The preparation method of protein gene comprises the following steps of: determining the related antigen existing between a tumor cell antigen and trichina positive serum and between a trichina antigen and tumor cell positive serum by utilizing an enzyme-linked immunosorbent assay; and screening a trichina cDNA (complementary deoxyribonucleic acid) expression library by utilizing SP2 / 0 hyperimmuneserum to obtain the related protein gene. The trichina and tumor cell related protein gene is a novel protein gene substance; tumor cells are sensitive to a variant identification substance, and the trichina and tumor cell related protein gene can produce strong specific and nonspecific immunoreaction to tumors, and the trichina and tumor cell related antigen is easy for preparation and industrialization.
Owner:JILIN UNIV

Ultra-VEGF-trap immune fusion protein, its preparation method and application

ActiveCN103304668AReduce blood supplyReduce oxygen supplyPeptide/protein ingredientsHybrid peptidesTumor-Related ProteinCancer research
The invention provides an Ultra-VEGF-trap immune fusion protein, which can be the protein in 1) or 2): 1) a protein composed of the amino acid sequence shown in SEQID.1; and 2) an anti-tumor related protein that is derived from 1) and is obtained by subjecting the amino acid sequence shown in SEQID.1 to substitution and / or deletion and / or adding by one or several amino acids. The invention also provides a construction method and application of the Ultra-VEGF-trap immune fusion protein. The immune fusion protein provided in the invention totally blocks the transduction pathway of VEGFs / VEGFRs, and has enormous value for treatment of multiple malignant tumors.
Owner:JIANGSU JIANDE BIOLOGICAL PHARMA

Use of phenol-soluble modulins for vaccine development

The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSMα, PSMγ and PSMδ peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo. Thus, the PSMα, PSMγ and PSMδ peptides bound to these antigens may be used in the development of vaccines for preventing or treating infectious diseases or cancer
Owner:PROYECTO DE BIOMEDICINA CIMA +1

Human CYR61 protein Ser188 site phosphorylation antigen, antibody and preparation method and application thereof

The invention discloses a human CYR61 protein Ser188 site phosphorylation antigen, an antibody and a preparation method and an application thereof, and relates to the technical field of antibodies andthe preparation. The antibody is prepared for an immune animal with an antigenic peptide through the active amino acid sequence shown in SEQ ID NO: 1. The phosphorylation antibody is useful for studying and kinase mediating phosphorylation and exploring various biological functions of CYR61 protein. In the practical application, the antibody can be utilized to study the action mechanism of the human CYR61 protein specific site phosphorylation modification in a specific biological event or a disease generation and development process and can also be used for detecting the difference in the expression of tumor-associated proteins after drug use to provide a potential action target for diagnosis and treatment of clinical tumor diseases.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Methods for screening inhibitors of tumor associated protein aggregation

The disclosure relates to the fields of protein aggregation diseases including cancer. More specifically, it concerns a screening method for identifying compounds that inhibit or disrupt co-aggregation of one or more member proteins of a disease-related protein aggregome, in particular, a tumor-associated protein aggregome. Further, disclosed are agents and compounds identified by the screening method that can be applied to prevent or to treat protein aggregation diseases, such as cancer.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +2

Tumour-associated protein detection method based on monomolecular counting

The invention discloses a tumour-associated protein detection method based on monomolecular counting. The tumour-associated protein detection method provided by the invention includes the following steps: 1) the tumour-associated protein molecule to be detected is captured onto a glass sheet by specificity interaction of ligand and receptor or specificity interaction of antibody and antigen, thenfluorescent labelled antibody directing to the tumour-associated protein molecule to be detected is added on the glass sheet, so as to obtain the glass sheet to be detected; 2) the glass sheet to be detected obtained by the step 1) is placed on the objective lens of a total internal reflection microscope to carry out detection of tumour-associated protein. The invention belongs to protein detection method, has the advantages of convenient operation, high detection sensibility, less sample usage and no enzyme amplification compared with similar technology and can detect low concentration protein molecule.
Owner:INST OF CHEM CHINESE ACAD OF SCI

Compositions and methods for diagnosis and therapy of cancers

The present invention relates to a method for improved diagnosis of cervical lesions based on detection of gene products encoded by the INK4a gene locus. According to the present invention an improvement in diagnosis may be achieved by assessing the presence or absence or the level of overexpression of at least two different gene products encoded by the INK4a gene locus. In another aspect the present invention relates to peptides derived from cell cycle regulatory proteins, the expression of which is altered in association with tumors in individuals. These peptides according to the present invention may be used for detection and therapy of tumors. For detection purposes the peptides may for example be used to detect antibodies directed against said peptides. In therapeutic respect the peptides may be used for immunotherapy or vaccination approaches. In therapeutic and diagnostic respect the peptides may be used in combination with one or more peptides derived from tumor associated proteins.
Owner:MTM LAB

Human CYR61 protein Ser167 locus phosphorylated antigen and antibody, as well as preparation methods and application thereof

The invention discloses a human CYR61 protein Ser167 locus phosphorylated antigen and antibody, as well as preparation methods and application thereof, and relates to the technical field of antibody and preparation thereof. The antibody is obtained for preparing an antigen peptide immune animal through active amino acid sequence shown in SEQ ID NO: 1. The phosphorylated antibody provided by the invention is conducive to the research of kinase which mediates the antibody to conduct phosphorylation and the discussion on various biological functions of CYR61 protein, facilitates researching the action mechanism of human CYR61 protein specific locus phosphorylation in specific biological events or disease occurrence and development process in actual application, can also be used for detectingthe difference of tumor-related protein expression after drug use, and provides potential action targets for the diagnosis and treatment of clinical tumor diseases.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Preparation and use of immune formulation

The invention relates to an immunity biological treatment that extractive protein from cancer organism or cancer cell, wherein it uses ammonia sulfate to deposit the protein component from cancer organism slurry or cancer cell crack liquid; the deposit contains requco protein group and relative cancer antigens; removes salt, concentrates, freezes and dries, the extractive can be directly prepared into injection of external agent to excite the immunity cell to the cancer patient, and the immunity system will recognize and kill cancer cell.
Owner:韩苏

Ultra-vegf-trap immune fusion protein, its preparation method and application

The invention provides an Ultra-VEGF-trap immune fusion protein, which can be the protein in 1) or 2): 1) a protein composed of the amino acid sequence shown in SEQID.1; and 2) an anti-tumor related protein that is derived from 1) and is obtained by subjecting the amino acid sequence shown in SEQID.1 to substitution and / or deletion and / or adding by one or several amino acids. The invention also provides a construction method and application of the Ultra-VEGF-trap immune fusion protein. The immune fusion protein provided in the invention totally blocks the transduction pathway of VEGFs / VEGFRs, and has enormous value for treatment of multiple malignant tumors.
Owner:JIANGSU JIANDE BIOLOGICAL PHARMA

Development and application of antibody gene chip

InactiveCN103376321AEnable Personalized TreatmentSolve the problem of in situ detection of large amounts of protein expressionMicrobiological testing/measurementMaterial analysisTumor-Related ProteinDisease
The invention relates to a technical invention which can be used for detecting a protein expression profile of a tissue slice. According to the technical invention, after a plurality of different antibodies are simultaneously bonded with a plurality of proteins to be detected of a tumor tissue, an identification V-D-J sequence subjected to PCR (Polymerase Chain Reaction) amplification is hybridized with an antibody gene chip, and the protein expression profile of the tumor tissue is displayed through a hybridization result; and certain protein in-situ expression statuses are selectively displayed through immunohistochemistry. The technical invention can be used for clinically detecting individual tumor related protein expression profiles of patients, solving the problem that a large number of protein expressions are subjected to in-situ detection for tissue slices, and directly applying a proteome research result to a clinical diagnosis process, thereby being an important premise for realizing individual treatment of diseases.
Owner:朱有凯

Multi-tumor combined detection kit and use method thereof

The invention discloses a multi-tumor combined detection kit. The multi-tumor combined detection kit comprises fluorescent microspheres capable of performing time resolution, a signal amplification system, a first tumor-associated protein, a sample to-be-detected object, a second tumor-associated protein and polymer fluorescent coding microspheres. The invention further discloses a use method of the kit. The method comprises the following steps: adding a to-be-detected sample; processing incubation oscillation, forming a reaction mixture of macromolecular fluorescence codes, second tumor-associated protein, a to-be-detected object, first tumor-associated protein and fluorescent microspheres capable of being subjected to time resolution; using a time-resolved flow type fluorescence detection device for carrying out high-throughput test; conveying sample liquid and sheath liquid to the flowing chamber together; after to-be-detected liquid particles sequentially pass through a flowing chamber capillary tube detection area, a first laser is activating, enabling a first laser fluorescence detector to collect fluorescence signals while a second laser is activated, and after short-life background fluorescence decay disappears, starting a second laser time-resolved fluorescence detection unit to collect signals for analysis and processing.
Owner:HANGZHOU GUANGKEANDE BIOTECHNOLOGY CO LTD

Calreticulin and fusion proteins

Compositions, methods, and uses of recombinant calreticulin protein that is modified to be expressed on the cell surface are presented. Preferably, the recombinant calreticulin protein is presented on the antigen presenting cell surface with a tumor associated protein to increase immunogenicity of the tumor cell in the tumor microenvironment.
Owner:NANTBIO INC +1

Antibodies to tumor associated proteins

A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and / or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
Owner:AGENSYS

A human cyr61 protein ser167 site phosphorylated antigen, antibody and its preparation method and application

The invention discloses a human CYR61 protein Ser167 site phosphorylated antigen, an antibody, a preparation method and application thereof, and relates to the technical field of the antibody and its preparation. The antibody is prepared by immunizing animals with the active amino acid sequence shown in SEQ ID NO: 1 as the antigen peptide. The phosphorylated antibody provided by the invention helps to study the kinases that mediate its phosphorylation, and to explore the various biological functions of the CYR61 protein; in practical applications, it is convenient to study the phosphorylation modification of specific sites of the human CYR61 protein in specific biological events Or the mechanism of action during the occurrence and development of the disease can also be used to detect the difference in the expression of tumor-associated proteins after medication, providing a potential target for the diagnosis and treatment of clinical tumor diseases.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Compositions and methods comprising protease-activated therapeutic agents

he disclosure relates to the engineering of collagen-binding modification of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which unmasks the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Accordingly, aspects of the disclosure relate to a polypeptide comprising a therapeutic agent linked to a masking agent through a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the association of the therapeutic agent to its therapeutic target, and further wherein the polypeptide is operatively linked to a collagen binding domain or a tumor-targeting agent.
Owner:UNIVERSITY OF CHICAGO

Compositions and methods comprising protease-activated therapeutic agents

The present disclosure relates to collagen binding modification engineering of masking therapeutic agents comprising one or more than one tumor-associated protease cleavage site. Upon exposure to a tumor-associated protease in the tumor microenvironment, the polypeptide is cleaved, which exposes the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Thus, aspects of the present disclosure relate to polypeptides comprising a therapeutic agent bound to a masking agent via a linker wherein the linker comprises one or more than one tumor-associated protease cleavage site, and wherein the masking agent blocks the attachment of a therapeutic agent to its therapeutic target, and wherein the polypeptide operably binds to a collagen binding domain or a tumor targeting agent.
Owner:UNIVERSITY OF CHICAGO

Antibodies to tumor associated proteins

A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and / or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
Owner:AGENSYS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products